I agree with both Popo and Redcuffs. A Reverse 10/1 stock split for BMSN, done after good news of Regen FDA approval of clinical trials for either HemaXellerate or dCellVax could be a positive think as the current Approved and Outstanding share numbers for this stock are too high in my opinion. Bringing AS from 5B down to 500,000,000 and OS from 2.95B to 295,000,000 million could be a good step and create more value in eyes of people looking at company and Approved Share count as long as it was done in positive time. Buyback program is bonus, but I don't see how you do that without revenue in place.
As long as BMSN reverse is not accompanied by Regen dilution. More important for Regen to keep overall AS low in my opinion as BMSN will eventually follow price lead of Regen.
But if Regen gets approval and IPOs at $1-$5, then BMSN value is .01-.05 a reverse 10/1 would put BMSN at .10 - .50 which would keep it out of sub-pennyland and be overall positive in my view for the future.
As long as BMSN reverse is not accompanied by Regen dilution. More important for Regen to keep overall AS low in my opinion as BMSN will eventually follow price lead of Regen.
But if Regen gets approval and IPOs at $1-$5, then BMSN value is .01-.05 a reverse 10/1 would put BMSN at .10 - .50 which would keep it out of sub-pennyland and be overall positive in my view for the future.
Quote:The only way a R/S would be ok is if it was done in the wake of positive moves and current PPS strength and not done due to weakness as most are. Say, a r/s after FDA approval etc. And if the company has money on hand (not likely) any R/S to get up listed following good news is also a good thing.
